Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
Year: 2009
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: GlaxoSmithKline
OpenAlex ID: W2117342140
